Literature DB >> 25302945

Biomarkers of rheumatoid arthritis-associated interstitial lung disease.

Juan Chen1, Tracy J Doyle, Yongliang Liu, Rohit Aggarwal, Xiaoping Wang, Yonghong Shi, Sheng Xiang Ge, Heqing Huang, Qingyan Lin, Wen Liu, Yongjin Cai, Diane Koontz, Carl R Fuhrman, Maria F Golzarri, Yushi Liu, Hiroto Hatabu, Mizuki Nishino, Tetsuro Araki, Paul F Dellaripa, Chester V Oddis, Ivan O Rosas, Dana P Ascherman.   

Abstract

OBJECTIVE: Interstitial lung disease (ILD) is a relatively common extraarticular manifestation of rheumatoid arthritis (RA) that contributes significantly to disease burden and excess mortality. The purpose of this study was to identify peripheral blood markers of RA-associated ILD that can facilitate earlier diagnosis and provide insight regarding the pathogenesis of this potentially devastating disease complication.
METHODS: Patients with RA who were enrolled in a well-characterized Chinese identification cohort or a US replication cohort were subclassified as having RA-no ILD, RA-mild ILD, or RA-advanced ILD, based on high-resolution computed tomography scans of the chest. Multiplex enzyme-linked immunosorbent assays (ELISAs) and Luminex xMAP technology were used to assess 36 cytokines/chemokines, matrix metalloproteinases (MMPs), and acute-phase proteins in the identification cohort. Unadjusted and adjusted logistic regression models were used to quantify the strength of association between RA-ILD and biomarkers of interest.
RESULTS: MMP-7 and interferon-γ-inducible protein 10 (IP-10)/CXCL10 were identified by multiplex ELISA as potential biomarkers for RA-ILD in 133 RA patients comprising the Chinese identification cohort (50 RA-no ILD, 41 RA-ILD, 42 RA-indeterminate ILD). The findings were confirmed by standard solid-phase sandwich ELISA in the Chinese identification cohort as well as an independent cohort of US patients with RA and different stages of ILD (22 RA-no ILD, 49 RA-ILD, 15 RA-indeterminate ILD), with statistically significant associations in both unadjusted and adjusted logistic regression analyses.
CONCLUSION: Levels of MMP-7 and IP-10/CXCL10 are elevated in the serum of RA patients with ILD, whether mild or advanced, supporting their value as pathogenically relevant biomarkers that can contribute to noninvasive detection of this extraarticular disease complication.
Copyright © 2015 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25302945      PMCID: PMC4624107          DOI: 10.1002/art.38904

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  37 in total

1.  Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.

Authors:  S Sato; T Nagaoka; M Hasegawa; C Nishijima; K Takehara
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

2.  Interstitial lung disease in rheumatoid arthritis.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

Review 3.  Subclinical interstitial lung disease: why you should care.

Authors:  Tracy J Doyle; Gary M Hunninghake; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2012-02-23       Impact factor: 21.405

4.  Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

Authors:  Lenny van Bon; Alsya J Affandi; Jasper Broen; Romy B Christmann; Renoud J Marijnissen; Lukasz Stawski; Giuseppina A Farina; Giuseppina Stifano; Allison L Mathes; Marta Cossu; Michael York; Cindy Collins; Mark Wenink; Richard Huijbens; Roger Hesselstrand; Tore Saxne; Mike DiMarzio; Dirk Wuttge; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Maureen Mayes; Yanhui Deng; Joost P H Drenth; Jacqueline de Graaf; Martin den Heijer; Cees G M Kallenberg; Marc Bijl; Arnoud Loof; Wim B van den Berg; Leo A B Joosten; Vanessa Smith; Filip de Keyser; Rafaella Scorza; Claudio Lunardi; Piet L C M van Riel; Madelon Vonk; Waander van Heerde; Stephan Meller; Bernhard Homey; Lorenzo Beretta; Mark Roest; Maria Trojanowska; Robert Lafyatis; Timothy R D J Radstake
Journal:  N Engl J Med       Date:  2013-12-18       Impact factor: 91.245

5.  Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests.

Authors:  J K Dawson; H E Fewins; J Desmond; M P Lynch; D R Graham
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

6.  Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.

Authors:  K E Greene; T E King; Y Kuroki; B Bucher-Bartelson; G W Hunninghake; L S Newman; H Nagae; R J Mason
Journal:  Eur Respir J       Date:  2002-03       Impact factor: 16.671

Review 7.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

8.  Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Lisa Harlow; Ivan O Rosas; Bernadette R Gochuico; Ted R Mikuls; Paul F Dellaripa; Chester V Oddis; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2013-04

9.  Lung volumes and emphysema in smokers with interstitial lung abnormalities.

Authors:  George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

10.  Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease.

Authors:  Juan Chen; YongHong Shi; XiaoPing Wang; Heqing Huang; Dana Ascherman
Journal:  Clin Dev Immunol       Date:  2013-07-31
View more
  37 in total

Review 1.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

2.  Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Authors:  Md Yuzaiful Md Yusof; Angela Kabia; Michael Darby; Giovanni Lettieri; Paul Beirne; Edward M Vital; Shouvik Dass; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

3.  Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Authors:  Tracy J Doyle; Avignat S Patel; Hiroto Hatabu; Mizuki Nishino; Guodong Wu; Juan C Osorio; Maria F Golzarri; Andres Traslosheros; Sarah G Chu; Michelle L Frits; Christine K Iannaccone; Diane Koontz; Carl Fuhrman; Michael E Weinblatt; Souheil Y El-Chemaly; George R Washko; Gary M Hunninghake; Augustine M K Choi; Paul F Dellaripa; Chester V Oddis; Nancy A Shadick; Dana P Ascherman; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

4.  Baseline Characteristics and Progression of a Spectrum of Interstitial Lung Abnormalities and Disease in Rheumatoid Arthritis.

Authors:  Leticia Kawano-Dourado; Tracy J Doyle; Karina Bonfiglioli; Márcio V Y Sawamura; Renato H Nakagawa; Fábio E Arimura; Hye J Lee; Diana Arrais de Souza Rangel; Cleonice Bueno; Carlos R R Carvalho; Maria Laura Sabbag; Camila Molina; Ivan O Rosas; Ronaldo A Kairalla
Journal:  Chest       Date:  2020-05-16       Impact factor: 9.410

Review 5.  Genetic and environmental risk factors for rheumatoid arthritis.

Authors:  Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-09-18       Impact factor: 4.098

Review 6.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 7.  Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms.

Authors:  Francisco Paulin; Tracy J Doyle; Elaine A Fletcher; Dana P Ascherman; Ivan O Rosas
Journal:  Rev Invest Clin       Date:  2015 Sep-Oct       Impact factor: 1.451

8.  Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.

Authors:  Argyris Tzouvelekis; Jose D Herazo-Maya; Martin Slade; Jen-Hwa Chu; Giuseppe Deiuliis; Changwan Ryu; Qin Li; Koji Sakamoto; Gabriel Ibarra; Hongyi Pan; Mridu Gulati; Danielle Antin-Ozerkis; Erica L Herzog; Naftali Kaminski
Journal:  Respirology       Date:  2016-10-19       Impact factor: 6.424

9.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

Review 10.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.

Authors:  Yoel Brito; Marilyn K Glassberg; Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.